NCT00403325已完成1 期
Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.
Vitreous -Retina- Macula Consultants of New York1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2006年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of chronic central serous retinopathy (CSC)
研究概览
简要总结
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
详细描述
This is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 days (± 2 days) for 3 injections. Thereafter they are to be evaluated every month until month 12. Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A history of persistent central serous chorioretinopathy present for at least 3 months Best-corrected visual acuity (BCVA) of 20/40 (73 letters on the ETDRS chart) to light perception as measured by ETDRS protocol refraction.
- •No signs of choroidal neovascularization
- •Documented subfoveal fluid by OCT
- •Active leak associated with the subfoveal fluid
- •The ability and willingness to provide written informed consent
排除标准
- •Prior treatment with laser or PDT
- •Have uncontrolled hypertension
- •Have a history of thromboembolic events including stroke, transient ischemic attacks, and myocardial infarction
- •Have use of or need for continued anticoagulation therapy, except aspirin 325 mg/day.
- •Are receiving or require chronic concomitant therapy with systemic (> 5 mg) or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for 14 or more consecutive days at any time within 6 months prior to screening
- •Previously vitrectomized eyes.
- •Had allergic reactions to fluorescein dye or lack of venous access.
- •Any other additional ocular diseases which could irreversibly compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy (AION), age related macular degeneration (AMD), retinal detachment, severe cataracts, etc.
- •An anticipated need for ocular surgery during the duration of the trial.
- •Within 1 month prior to screening, have had intra ocular surgeries (including cataract surgery) in the study eye.
- •Intravitreal triamcinolone or bevacizumab in the previous 2 months
- •Uncontrolled glaucoma (IOP > 24 mmHg) on greater than 3 medications.
- •Within 1 month prior to screening had YAG laser capsulotomy in the study eye
- •Have received any other systemic experimental drug within 12 weeks prior to enrollment.
- •Rubeosis iridis or neovascular glaucoma
- •Any untreated rhegmatogenous retinal detachment.
- •A visual acuity of worse than 20/400 in the fellow eye.
- •Unwilling or unable to follow or comply with all study related procedures.
结局指标
主要结局
To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of chronic central serous retinopathy (CSC)
次要结局
- Mean change in VA compared to baseline at month 6 and month 12
- Proportion of patients with 20/20 vision at month 6 and 12 as compared to baseline
- Proportion of patients losing ≤ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 6 and 12
- Proportion of patients gaining ≥ 15 letters as measured by ETDRS visual refraction at 4 meters compared to baseline at month 6 and 12
- Change in subretinal fluid (as measured by optical coherence tomography) from baseline at month 3, 6, 9 and 12
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular EdemaRetinal Vein OcclusionNCT00403039Vitreous -Retina- Macula Consultants of New York41
已完成
不适用
Treatment of Epiretinal Membranes With RanibizumabEpiretinal MembraneNCT01238393Queen's University11
已完成
1 期
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular DegenerationMacular DegenerationNCT00395707The National Retina Institute20
撤回
2 期
Study of Uveitic Macular Edema Treated With Ranibizumab or SteroidsMacular EdemaUveitisNCT00846625University of Utah
已完成
1 期
Topical Interferon Gamma-1b for Central Serous ChorioretinopathyRetinal DiseaseMacular DiseaseNCT01468337National Eye Institute (NEI)5